SHPH (Shuttle Pharmaceuticals Holdings) EBIT: $-10.75 Mil (TTM As of Mar. 2026)


SHPH Shuttle Pharmaceuticals Holdings Inc SHPH
24 GF Score
Price $3.98
! 1 Warning Sign
View Full Analysis

What is Shuttle Pharmaceuticals Holdings EBIT?

Shuttle Pharmaceuticals Holdings SHPH +6.35% 24 EBIT is $-10.75 Mil as of Mar. 2026. GuruFocus rates SHPH with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Shuttle Pharmaceuticals Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-2.14 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-10.75 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shuttle Pharmaceuticals Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was -75.55%. Shuttle Pharmaceuticals Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -7,746.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shuttle Pharmaceuticals Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -739.85%.


Shuttle Pharmaceuticals Holdings  (NAS:SHPH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shuttle Pharmaceuticals Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-8.868 * ( 1 - 0% )/( (12.05 + 11.426)/ 2 )
=-8.868/11.738
=-75.55 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shuttle Pharmaceuticals Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.56/( ( (0.12 + max(-7.721, 0)) + (0.101 + max(-6.853, 0)) )/ 2 )
=-8.56/( ( 0.12 + 0.101 )/ 2 )
=-8.56/0.1105
=-7,746.61 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.169) - (5.89 + 0 + 2)
=-7.721

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.373) - (6.226 + 0 + 2)
=-6.853

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shuttle Pharmaceuticals Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-10.75/1.453
=-739.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shuttle Pharmaceuticals Holdings EBIT Related Terms


Shuttle Pharmaceuticals Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Shuttle Pharmaceuticals Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shuttle Pharmaceuticals Holdings EBIT Chart

Shuttle Pharmaceuticals Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -1.10 -4.52 -4.00 -7.79 -11.65

Shuttle Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.04 -3.69 -2.33 -2.60 -2.14

SHPH vs PRFX, CBIH, UPC: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shuttle Pharmaceuticals Holdings EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shuttle Pharmaceuticals Holdings's EV-to-EBIT falls into.


SHPH
24GF Score
Shuttle Pharmaceuticals Holdings Inc SHPH
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shuttle Pharmaceuticals Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-10.75 Mil mean?
Shuttle Pharmaceuticals Holdings (SHPH) has a EBIT of $-10.75 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shuttle Pharmaceuticals Holdings.
Is Shuttle Pharmaceuticals Holdings' EBIT too high?
Shuttle Pharmaceuticals Holdings' current EBIT is $-10.75 Mil. Overall, Shuttle Pharmaceuticals Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Shuttle Pharmaceuticals Holdings' EBIT compare to PRFX and CBIH?
Shuttle Pharmaceuticals Holdings' EBIT of $-10.75 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shuttle Pharmaceuticals Holdings. Shuttle Pharmaceuticals Holdings's current EBIT is $-10.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shuttle Pharmaceuticals Holdings stock overvalued right now?
Shuttle Pharmaceuticals Holdings (SHPH) has a current EBIT of $-10.75 Mil. The current EBIT is $-10.75 Mil. Shuttle Pharmaceuticals Holdings' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shuttle Pharmaceuticals Holdings (SHPH), the current EBIT is $-10.75 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shuttle Pharmaceuticals Holdings Business Description

Address 401 Professional Drive, Suite 260, Gaithersburg, MD, USA, 20879
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score

Get the complete analysis for SHPH

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.98
Price